ANAPTYSBIO, INC. Expense Breakdown
No Expense Breakdown for ANAB on this site yet.
- 2026-03-31: External Expenses $18.66M; Internal Expenses $15.33M; Anb033 $9.30M; Rosnilimab $4.59M.
- 2025-03-31: External Expenses $27.59M; Internal Expenses $13.59M; Anb033 $3.80M; Rosnilimab $15.03M.
Source checked: the stored Expense Breakdown page for ANAB.
Expenses by product
Research And Development Expense Reversal Excluding Acquired In Process Cost: each quarter (3 month)
| Quarter end | External Expenses | Internal Expenses | Anb033 | Rosnilimab | Preclinical and Other Unallocated Costs | Anb101 | Others |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | $18.66M | $15.33M | $9.30M | $4.59M | $3.30M | $1.48M | Imsidolimab $21.00K Anb032 -$31.00K |
| 2025-03-31 | $27.59M | $13.59M | $3.80M | $15.03M | $3.93M | $1.48M | Anb032 $3.54M Imsidolimab -$189.00K |
General and Administrative Expense: each quarter (3 month)
| Quarter end | External Expenses | Internal Expenses |
|---|---|---|
| 2026-03-31 | $12.12M | $14.08M |
| 2025-03-31 | $5.54M | $8.59M |
Income Tax Expense (Benefit): each quarter (3 month)
| Quarter end | Royalty Management Company | Biopharma Company |
|---|---|---|
| 2026-03-31 | $40.00K | $0.00 |
| 2025-03-31 | $44.00K | $0.00 |
Operating expenses: each quarter (3 month)
| Quarter end | Royalty Management Company | Biopharma Company |
|---|---|---|
| 2026-03-31 | $7.38M | $52.81M |
| 2025-03-31 | $4.03M | $51.28M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |